retatrutide clinical trial south africa results ⭐️topline from TRIUMPH-1, a Phase 3 clinical trial evaluating #retatrutide, an investigational GIP / GLP-1 / glucagon triple hormone receptor agonist, in adults with obesity or “ VisualAbstract: Retatrutide reduces body weight

Zepbound (Injectable) Zepbound (tirzepatide) injectable, a FDA-approved dual GIP and GLP-1 receptor agonist, taken once a week using single use vials and insulin syringes

Triglyceride levels dropped by 28%, LDL cholesterol by 12%, and the ratio of total cholesterol to HDL improved

Li T, Jiao JJ, Hlscher C, Wu MN, Zhang J, Tong JQ, et al

More broadly, a clinician-supervised GLP-1 program, such as GLP-1 Longevity Care, addresses the single most important determinant of outcomes with these medications: ongoing clinical management

OrderlyMeds advertises 48-hour approval and 510-day fulfillment, but my order took 20 days from sign-up to delivery

While GIPs role in weight loss was historically less understood, research published in Cell Metabolism (2021) has revealed that GIP signaling in the brain contributes to appetite suppression and may enhance the bodys ability to mobilize and utilize stored fat